Report of Foreign Issuer (6-k)
February 20 2018 - 12:08PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
20 February
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the
'
Company
')
Shares sold to meet tax liabilities
Following the vesting of the pre-tax awards granted in 2015 under
the GlaxoSmithKline Deferred Annual Bonus Plan ('DABP') on 15
February 2018 and as notified on 16 February 2018, the
notifications that follow reflect change in the interests of the
Person Discharging Managerial Responsibilities ('PDMRs') in
American Depositary Shares ('ADS') of the Company arising from the
sale of ADSs to meet tax liabilities.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D E Troy
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature of
the
transaction
|
The sale of ADSs to meet tax liabilities further to the vesting of
awards granted in 2015 under the Company's 2009 Deferred Annual
Bonus Plan-Deferred Bonus and Matching Awards.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$37.4803
|
3,480 (Deferred)
|
$37.4803
|
2,520 (Matching)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
6,000
$37.4803
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
20, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024